<DOC>
	<DOCNO>NCT01136421</DOCNO>
	<brief_summary>Treatment short act β2 agonist exacerbation COPD result clinical improvement . It establish whether combine short act β2 agonist bronchodilator effective β2 agonist alone . The aim study evaluate efficacy safety combination SABA MgSO4 comparison SABA ipratropium bromide ( IB ) patient attend emergency department AECOPD .</brief_summary>
	<brief_title>Magnesium Sulfate Versus Ipratropuim Bromide Acute Exacerbation Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Patients present emergency department exacerbation COPD randomize receive nebulised ipratropuim bromide combine nebulised intravenous bolus magnesium sulfate 1 hour .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>40 year old know suspect COPD base pulmonary function test , arterial blood gas , clinical history , physical examination , chest radiograph worsen dyspnea within 2 week , partial pressure arterial carbon dioxide ( PaCO2 ) &gt; 45 mmHg respiratory rate &gt; 24/min arterial pH &lt; 7.35 partial pressure arterial oxygen ( PaO2 ) &lt; 50 mmHg room air hypersensitivity anticholinergic magnesium sulfate patient receive anticholinergic within 6 hour ED admission systolic arterial pressure &lt; 90 mmHg need vasoactive drug</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>COPD exacerbation</keyword>
	<keyword>Magnesium sulfate</keyword>
	<keyword>Ipratropium bromide</keyword>
	<keyword>Emergency departement</keyword>
</DOC>